Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab

By sjmartinez • May 13, 2025

Kim GH, Zhang X, Brown MS, Poole L, Goldin J. Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab. BMJ Open. 2025 May 12;15(5):e094559. doi: 10.1136/bmjopen-2024-094559. PMID: 40355288.

Tags: Chest imaging, Computed tomography, interstitial lung disease, Patient reported outcome measures, Publications, Pulmonary Disease, Pulmonary, Critical Care & Sleep Medicine, QUALITATIVE RESEARCH

ATS Core Curriculum 2026 Adult Pulmonary Medicine: Pulmonary Hypertension Diagnosis and Management

Cho JL, Camac E, Bernardo RJ, Carmona H, Del Valle KT, Forbes LM, Kolaitis NA, Mathai SK, Maximous SI, Melamed KH, Peck TJ, Soffler M,[...]

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study

Cromer SJ, Tesfaye H, Cho H, Wexler DJ, Ortega-Montiel J, Schmedt N, Shay CM, Paik JM, Patorno E. Effects of Empagliflozin on Cardiovascular Outcomes Are[...]